Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Comprehensive comparison of three commercial human whole-exome capture platforms

Open access
Asan, Xu, Yu, Jiang, Hui, Tyler-Smith, Chris, Xue, Yali, Jiang, Tao, Wang, Jiawei, Wu, Mingzhi, Liu, Xiao, Tian, Geng, Wang, Jun, Wang, Jian, Yang, Huangming, Zhang, Xiuqing · 2011 · Genome Biology

Abstract

Background: Exome sequencing, which allows the global analysis of protein coding sequences in the human genome, has become an effective and affordable approach to detecting causative genetic mutations in diseases. Currently, there are several commercial human exome capture platforms; however, the relative performances of these have not been characterized sufficiently to know which is best for a particular study. Results: We comprehensively compared three platforms: NimbleGen's Sequence Capture Array and SeqCap EZ, and Agilent's SureSelect. We assessed their performance in a variety of ways, including number of genes covered and capture efficacy. Differences that may impact on the choice of platform were that Agilent SureSelect covered approximately 1,100 more genes, while NimbleGen provided better flanking sequence capture. Although all three platforms achieved similar capture specificity of targeted regions, the NimbleGen platforms showed better uniformity of coverage and greater genotype sensitivity at 30- to 100-fold sequencing depth. All three platforms showed similar power in exome SNP calling, including medically relevant SNPs. Compared with genotyping and whole-genome sequencing data, the three platforms achieved a similar accuracy of genotype assignment and SNP detection. Importantly, all three platforms showed similar levels of reproducibility, GC bias and reference allele bias. Conclusions: We demonstrate key differences between the three platforms, particularly advantages of solutions over array capture and the importance of a large gene target set.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/gb-2011-12-9-r95

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 164

Metadata

Authors
Asan, Xu, Y., Jiang, H., Tyler-Smith, C., Xue, Y., Jiang, T., Wang, J., Wu, M., Liu, X., Tian, G., Wang, J., Wang, J., Yang, H., & Zhang, X.
Venue
Genome Biology
Published
2011-09-28
Volume
12
Issue
9
Pages
R95-R95
ISSN
  • 1465-6906 (ISSN-L)
  • 1474-760X
OpenAlex
W2140247415
Cited by
164
References
10
FWCI
12.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive comparison of three commercial human whole-exome capture platforms. https://app.cochat.ai/papers/10.1186/gb-2011-12-9-r95
The paper
Asan, Xu, Y., Jiang, H., Tyler-Smith, C., Xue, Y., Jiang, T., Wang, J., Wu, M., Liu, X., Tian, G., Wang, J., Wang, J., Yang, H., & Zhang, X. (2011). Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biology. https://doi.org/10.1186/gb-2011-12-9-r95

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.